Author

Nicole Houck

Observed name: N Houck

Institution: Johnson & Johnson (United States)

Observed institutions: Johnson & Johnson (United States), Janssen Research & Development (United States)

OpenAlex ID: A5093087843

S1449 Efficacy and Safety of Icotrokinra, a Targeted Oral Peptide That Selectively Blocks IL-23 Receptor Activation, in Ulcerative Colitis: Results From Week 28 of ANTHEM-UC, a Phase 2b Dose-Ranging Trial

2025 · Vipul Jairath, Britta Siegmund, et al. · The American Journal of Gastroenterology · 1

P74 Improvement in inflammatory biomarkers through week-12 in guselkumab-treated patients with moderately-to-severely active ulcerative colitis: results from phase-3 QUASAR induction study

2024 · Kuan-hsiang Huang, Tadakazu Hisamatsu, et al. · Poster presentations · 1

S1063 Improvement in Inflammatory Biomarker Levels Through Week 12 in Moderately to Severely Active Ulcerative Colitis Patients Treated With Guselkumab: Results From the Phase 3 QUASAR Induction Study

2023 · Tadakazu Hisamatsu, Laurent Peyrin-Biroulet, et al. · The American Journal of Gastroenterology · 1

Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis

2026 · Maria T. Abreu, Britta Siegmund, et al. · New England Journal of Medicine

P171 Efficacy and safety of icotrokinra, a targeted oral peptide that blocks il-23 receptor activation, in ulcerative colitis: results from ANTHEM-UC

2026 · Jimmy Limdi, Vipul Jairath, et al. · E-Posters

O60 Icotrokinra, a targeted oral peptide that blocks IL-23 receptor activation, in moderate-to-severe ulcerative colitis: week 12 results from ANTHEM-UC

2026 · Jimmy Limdi, Maria T Abreu, et al.

487 Efficacy of Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, in Ulcerative Colitis Patients With or Without Prior Intolerance or Inadequate Response to Advanced Therapies: Results From the Anthem-uc Study

2026 · Edward V. Loftus, Vipul Jairath, et al. · Gastrointestinal Endoscopy

487 Efficacy of Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, in Ulcerative Colitis Patients With or Without Prior Intolerance or Inadequate Response to Advanced Therapies: Results From the Anthem-uc Study

2026 · Edward V. Loftus, Vipul Jairath, et al. · Gastroenterology

Su1860 GUSELKUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY PROMIS-29 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY

2024 · Julián Panés, Axel Dignass, et al. · Gastroenterology

DOP49 Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study

2024 · J Panés, A Dignass, et al. · Journal of Crohn s and Colitis

Works count: 10

Citation count: 3

H-index: 1

I10-index: